Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial)

Journal of the National Cancer Center · Elsevier

Аннотация

Publication date: August 2026 Source: Journal of the National Cancer Center, Volume 6, Issue 4 Author(s): Yi Miao, Ming Liu, Shuchao Qin, Fei Li, Jin Zhang, Hongling Peng, Chunyan Ji, Luomengjia Dai, Ziyuan Zhou, Chongyang Ding, Zhen Wang, Yeqin Sha, Tonglu Qiu, Hanning Tang, Hui Jin, Lei Fan, Wei Xu, Jianyong Li, Yi Xia, Huayuan Zhu

Читать у издателя →

Похожие статьи